GEP-NECs
Stories
-
Novatek registers Phase 2/3 trial of NP-101 in GEP-NECs
The study, led by Novatek Pharmaceuticals, plans to enroll an estimate of 381 participants to evaluate the safety and efficacy of NP-101 combined with Nivolumab and Ipilimumab versus placebo in refractory advanced and metastatic gastroenteropancreatic neuroendocrine carcinomas. It is planned to begin in January 2027 and reach primary completion in December 2029.